Sign In
Buy CRTX
$2.20
+0 (+0%)
At Close: Nov 04, 2022
Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease
08:52am, Tuesday, 16'th Feb 2021
Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension (OLE) phase of Phase 2/3 GAIN trial of Cortexyme Inc (NASDAQ: C
Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer's Disease
09:13pm, Monday, 15'th Feb 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, received a letter from
Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion
04:06pm, Wednesday, 10'th Feb 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therap
Cortexyme: A Fresh Perspective In Alzheimer's
08:00am, Tuesday, 12'th Jan 2021
CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
09:47am, Wednesday, 06'th Jan 2021
Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseas
4,400 Shares in Cortexyme, Inc. (NASDAQ:CRTX) Acquired by TD Asset Management Inc.
06:16am, Thursday, 17'th Sep 2020
TD Asset Management Inc. acquired a new stake in Cortexyme, Inc. (NASDAQ:CRTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commiss
Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update
12:00pm, Monday, 17'th Aug 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for th
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
04:10am, Sunday, 16'th Aug 2020
Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation. Calliditas Therapeutics inks deal for Genkyotex Acquisition.
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients
12:00pm, Friday, 14'th Aug 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease (AD) has reached 500 patients toward the study’s previously announced enrollment target of
We're Hopeful That Cortexyme (NASDAQ:CRTX) Will Use Its Cash Wisely
12:11pm, Wednesday, 12'th Aug 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
12:10pm, Wednesday, 12'th Aug 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020
08:05pm, Thursday, 06'th Aug 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company
Bristol Myers Squibb NDA, And Other News: The Good, Bad And Ugly Of Biopharma
03:52pm, Thursday, 30'th Jul 2020
Bristol Myers Squibb resubmits multiple myeloma therapy application. Onconova reports progress of INSPIRE trial data analysis.
Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020
12:00pm, Wednesday, 29'th Jul 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., th
